Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | FGFR2 N550H |
| Gene Variant Detail | |
| Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR2 Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| FGFR2 N550H | Advanced Solid Tumor | decreased response | FGFR Inhibitor (Pan) | Dovitinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing FGFR2 N550H demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597). | 23908597 |
| FGFR2 N550H | Advanced Solid Tumor | resistant | PD173074 | Preclinical | Actionable | In a preclinical study, transformed cells expressing FGFR2 N550H were resistant to treatment with PD173074 (PMID: 23908597). | 23908597 | |
| FGFR2 N550H | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | Ponatinib | Preclinical | Actionable | In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550H (PMID: 23908597). | 23908597 |
| FGFR2 N550H | Advanced Solid Tumor | predicted - sensitive | FGFR2 Inhibitor | TYRA-200 | Preclinical - Biochemical | Actionable | In a preclinical study, TYRA-200 inhibited FGFR2 N550H in an in vitro assay (Eur J Cancer 2022 Vol 174, Supp 1:S16). | detail... |
| FGFR2 N550H | Advanced Solid Tumor | predicted - sensitive | FGFR Inhibitor (Pan) | KIN-3248 | Preclinical - Biochemical | Actionable | In a preclinical study, KIN-3248 inhibited kinase activity of FGFR2 N550H in an in vitro assay (PMID: 38437671). | 38437671 |